Viking Therapeutics, Inc.

NASDAQ (USD): Viking Therapeutics, Inc. (VKTX)

Last Price

54.13

Today's Change

-1.26 (2.27%)

Day's Change

51.70 - 55.63

Trading Volume

3,666,380

Overview

Market Cap

5 Billion

Shares Outstanding

110 Million

Avg Volume

3,818,232

Avg Price (50 Days)

56.83

Avg Price (200 Days)

50.01

PE Ratio

-58.20

EPS

-0.93

Earnings Announcement

23-Oct-2024

Previous Close

55.39

Open

55.47

Day's Range

51.7 - 55.63

Year Range

8.28 - 99.41

Trading Volume

3,686,291

Price Change Highlight

1 Day Change

-2.27%

5 Day Change

-15.02%

1 Month Change

6.43%

3 Month Change

-3.32%

6 Month Change

-26.85%

Ytd Change

196.12%

1 Year Change

270.50%

3 Year Change

723.90%

5 Year Change

646.62%

10 Year Change

576.62%

Max Change

576.62%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment